Targeting airway inflammation in cystic fibrosis

References

• Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989 Sep 8;245(4922):1066–1073.
   PubMed Web of Science ®Google Scholar
• Cheng K, Ashby D, Smyth RL. Oral steroids for long-term use in cystic fibrosis. Cochrane Database Syst Rev. 2013 Jun;24(6):CD000407.
   Google Scholar
• Konstan MW, Davis PB. Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. Adv Drug Deliv Rev. 2002 Dec 5;54(11):1409–1423.
   PubMed Web of Science ®Google Scholar
• McElvaney OJ, Bergin DA, Adage T., et al. The effect of PA401 on interleukin-8 levels in airway samples of adult patients with cystic fibrosis. In: D21. Cystic fibrosis: new insights into airway infection and inflammation. American Thoracic Society; 2013. p. A5281–A5281.
   Google Scholar
• Altenburg J, de Graaff CS, van der Werf TS, et al. Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms. Respiration. 2011;81(1):67–74.
   PubMed Web of Science ®Google Scholar
• Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The pulmozyme study group. N Engl J Med. 1994 Sep 8;331(10):637–642.
   PubMed Web of Science ®Google Scholar
• Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006 Jan 19;354(3):229–240.
   PubMed Web of Science ®Google Scholar
• Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J. 2011 Nov;38(5):1071–1080.
   PubMed Web of Science ®Google Scholar
• Sadowska AM, Manuel YKB, De Backer WA. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm Pharmacol Ther. 2007;20(1):9–22.
   PubMed Web of Science ®Google Scholar
• Tam J, Nash EF, Ratjen F, et al. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst Rev. 2013 Jul;12(7):CD007168.
   Google Scholar
• Martin SL, Downey D, Bilton D, et al. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol. 2006 Feb;41(2):177–183.
   PubMed Web of Science ®Google Scholar
• Elborn JS, Perrett J, Forsman-Semb K, et al. Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis. Eur Respir J. 2012 Oct;40(4):969–976.
   PubMed Web of Science ®Google Scholar
• Woods DE, Cantin A, Cooley J, et al. Aerosol treatment with MNEI suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection. Pediatr Pulmonol. 2005 Feb;39(2):141–149.
   PubMed Web of Science ®Google Scholar
• Hatch RA, Schiller NL. Alginate lyase promotes diffusion of aminoglycosides through the extracellular polysaccharide of mucoid Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1998 Apr;42(4):974–977.
   PubMed Web of Science ®Google Scholar
• McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008 Nov 1;178(9):921–928.
   PubMed Web of Science ®Google Scholar
• Schuster A, Haliburn C, Doring G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax. 2013 Apr;68(4):344–350.
   PubMed Web of Science ®Google Scholar
• Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med. 2013 May 23;368(21):1963–1970.
   PubMed Web of Science ®Google Scholar
• Birrer P, McElvaney NG, Rudeberg A, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med. 1994 Jul;150(1):207–213.
   PubMed Web of Science ®Google Scholar
• Rosenfeld M, Emerson J, Accurso F, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol. 1999 Nov;28(5):321–328.
   PubMed Web of Science ®Google Scholar
• Pillarisetti N, Williamson E, Linnane B, et al. Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med. 2011 Jul 1;184(1):75–81.
   PubMed Web of Science ®Google Scholar
• Sagel SD, Gibson RL, Emerson J, et al. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr. 2009 Feb;154(2):183–188.
   PubMed Web of Science ®Google Scholar
• Chotirmall SH, Smith SG, Gunaratnam C, et al. Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis. N Engl J Med. 2012 May 24;366(21):1978–1986.
   PubMed Web of Science ®Google Scholar
• Balough K, McCubbin M, Weinberger M, et al. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol. 1995 Aug;20(2):63–70.
   PubMed Web of Science ®Google Scholar
• Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med. 1995 Apr;151(4):1075–1082.
   PubMed Web of Science ®Google Scholar
• Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1197–1204.
   PubMed Web of Science ®Google Scholar
• Dakin CJ, Numa AH, Wang H, et al. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am J Respir Crit Care Med. 2002 Apr 1;165(7):904–910.
   PubMed Web of Science ®Google Scholar
• Stoltz DA, Meyerholz DK, Pezzulo AA, et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med. 2010 Apr 28;2(29):29ra31.
   PubMed Web of Science ®Google Scholar
• Griese M, Kappler M, Gaggar A, et al. Inhibition of airway proteases in cystic fibrosis lung disease. Eur Respir J. 2008 Sep;32(3):783–795.
   PubMed Web of Science ®Google Scholar
• Geraghty P, Rogan MP, Greene CM, et al. Neutrophil elastase up-regulates cathepsin B and matrix metalloprotease-2 expression. J Immunol. 2007 May 1;178(9):5871–5878.
   PubMed Web of Science ®Google Scholar
• Greene CM, McElvaney NG. Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery. Br J Pharmacol. 2009 Oct;158(4):1048–1058.
   PubMed Web of Science ®Google Scholar
• Kelly E, Greene CM, McElvaney NG. Targeting neutrophil elastase in cystic fibrosis. Expert Opin Ther Targets. 2008 Feb;12(2):145–157.
   PubMed Web of Science ®Google Scholar
• Taggart C, Coakley RJ, Greally P, et al. Increased elastase release by CF neutrophils is mediated by tumor necrosis factor-alpha and interleukin-8. Am J Physiol Lung Cell Mol Physiol. 2000 Jan;278(1):L33–41.
   PubMed Web of Science ®Google Scholar
• Vega-Carrascal I, Reeves EP, Niki T, et al. Dysregulation of TIM-3-galectin-9 pathway in the cystic fibrosis airways. J Immunol. 2011 Mar 1;186(5):2897–2909.
   PubMed Web of Science ®Google Scholar
• Vandivier RW, Fadok VA, Ogden CA, et al. Impaired clearance of apoptotic cells from cystic fibrosis airways. Chest. 2002 Mar;121(3 Suppl):89S.
   PubMed Web of Science ®Google Scholar
• Hartl D, Latzin P, Hordijk P, et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med. 2007 Dec;13(12):1423–1430.
   PubMed Web of Science ®Google Scholar
• Pohl K, Hayes E, Keenan J, et al. A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy. Blood. 2014 Aug 14;124(7):999–1009.
   PubMed Web of Science ®Google Scholar
• Coakley RJ, Taggart C, Canny G, et al. Altered intracellular pH regulation in neutrophils from patients with cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2000 Jul;279(1):L66–74.
   PubMed Web of Science ®Google Scholar
• Coakley RJ, Taggart C, McElvaney NG, et al. Cytosolic pH and the inflammatory microenvironment modulate cell death in human neutrophils after phagocytosis. Blood. 2002 Nov 1;100(9):3383–3391.
   PubMed Web of Science ®Google Scholar
• Coakley RJ, Taggart C, Greene C, et al. Ambient pCO2 modulates intracellular pH, intracellular oxidant generation, and interleukin-8 secretion in human neutrophils. J Leukoc Biol. 2002 Apr;71(4):603–610.
   PubMed Web of Science ®Google Scholar
• Witko-Sarsat V, Rieu P, Descamps-Latscha B, et al. Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest. 2000 May;80(5):617–653.
   PubMed Web of Science ®Google Scholar
• Faurschou M, Borregaard N. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect. 2003 Nov;5(14):1317–1327.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004 Mar 5;303(5663):1532–1535.
   PubMed Web of Science ®Google Scholar
• Tecchio C, Micheletti A, Cassatella MA. Neutrophil-derived cytokines: facts beyond expression. Front Immunol. 2014;5:508.
   PubMed Web of Science ®Google Scholar
• Painter RG, Valentine VG, Lanson NA Jr., et al. CFTR expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. Biochemistry. 2006 Aug 29;45(34):10260–10269.
   PubMed Web of Science ®Google Scholar
• Painter RG, Bonvillain RW, Valentine VG, et al. The role of chloride anion and CFTR in killing of Pseudomonas aeruginosa by normal and CF neutrophils. J Leukoc Biol. 2008 Jun;83(6):1345–1353.
   PubMed Web of Science ®Google Scholar
• Bruscia EM, Bonfield TL. Cystic fibrosis lung immunity: the role of the macrophage. J Innate Immun. 2016;8(6):550–563.
   PubMed Web of Science ®Google Scholar
• Armstrong DA, Nymon AB, Ringelberg CS, et al. Pulmonary microRNA profiling: implications in upper lobe predominant lung disease. Clin Epigenetics. 2017;9:56.
   PubMed Web of Science ®Google Scholar
• Leveque M, Le Trionnaire S, Del Porto P, et al. The impact of impaired macrophage functions in cystic fibrosis disease progression. J Cyst Fibros. 2017 Jul;16(4):443–453.
   PubMed Web of Science ®Google Scholar
• Tarique AA, Sly PD, Holt PG, et al. CFTR-dependent defect in alternatively-activated macrophages in cystic fibrosis. J Cyst Fibros. 2017 Jul;16(4):475–482.
   PubMed Web of Science ®Google Scholar
• Di A, Brown ME, Deriy LV, et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol. 2006 Sep;8(9):933–944.
   PubMed Web of Science ®Google Scholar
• Del Porto P, Cifani N, Guarnieri S, et al. Dysfunctional CFTR alters the bactericidal activity of human macrophages against Pseudomonas aeruginosa. PLoS One. 2011;6(5):e19970.
   PubMed Web of Science ®Google Scholar
• Van de Weert-van Leeuwen PB, Van Meegen MA, Speirs JJ, et al. Optimal complement-mediated phagocytosis of Pseudomonas aeruginosa by monocytes is cystic fibrosis transmembrane conductance regulator-dependent. Am J Respir Cell Mol Biol. 2013 Sep;49(3):463–470.
   PubMed Web of Science ®Google Scholar
• Zhang PX, Murray TS, Villella VR, et al. Reduced caveolin-1 promotes hyperinflammation due to abnormal heme oxygenase-1 localization in lipopolysaccharide-challenged macrophages with dysfunctional cystic fibrosis transmembrane conductance regulator. J Immunol. 2013 May 15;190(10):5196–5206.
   PubMed Web of Science ®Google Scholar
• Carroll TP, Greene CM, Taggart CC, et al. Viral inhibition of IL-1- and neutrophil elastase-induced inflammatory responses in bronchial epithelial cells. J Immunol. 2005 Dec 1;175(11):7594–7601.
   PubMed Web of Science ®Google Scholar
• Hector A, Schafer H, Poschel S, et al. Regulatory T-cell impairment in cystic fibrosis patients with chronic pseudomonas infection. Am J Respir Crit Care Med. 2015 Apr 15;191(8):914–923.
   PubMed Web of Science ®Google Scholar
• Bayes HK, Bicknell S, MacGregor G, et al. T helper cell subsets specific for Pseudomonas aeruginosa in healthy individuals and patients with cystic fibrosis. PLoS One. 2014;9(2):e90263.
   PubMed Web of Science ®Google Scholar
• Raga S, Julia MR, Crespi C, et al. Gammadelta T lymphocytes from cystic fibrosis patients and healthy donors are high TNF-alpha and IFN-gamma-producers in response to Pseudomonas aeruginosa. Respir Res. 2003;4:9.
   PubMed Web of Science ®Google Scholar
• Tiringer K, Treis A, Fucik P, et al. A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2013 Mar 15;187(6):621–629.
   PubMed Web of Science ®Google Scholar
• Hiemstra PS, McCray PB Jr., Bals R. The innate immune function of airway epithelial cells in inflammatory lung disease. Eur Respir J. 2015 Apr;45(4):1150–1162.
   PubMed Web of Science ®Google Scholar
• Parker D, Prince A. Innate immunity in the respiratory epithelium. Am J Respir Cell Mol Biol. 2011 Aug;45(2):189–201.
   PubMed Web of Science ®Google Scholar
• Stoltz DA, Meyerholz DK, Welsh MJ. Origins of cystic fibrosis lung disease. N Engl J Med. 2015 Apr 16;372(16):1574–1575.
   PubMed Web of Science ®Google Scholar
• De Rose V, Molloy K, Gohy S, et al. Airway epithelium dysfunction in cystic fibrosis and COPD. Mediators Inflamm. 2018;2018:1309746.
   PubMed Web of Science ®Google Scholar
• Collawn JF, Matalon S. CFTR and lung homeostasis. Am J Physiol Lung Cell Mol Physiol. 2014 Dec 15;307(12):L917–23.
   PubMed Web of Science ®Google Scholar
• Dalemans W, Barbry P, Champigny G, et al. Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature. 1991 Dec 19–26;354(6354):526–528.
   PubMed Web of Science ®Google Scholar
• Rabeh WM, Bossard F, Xu H, et al. Correction of both NBD1 energetics and domain interface is required to restore deltaF508 CFTR folding and function. Cell. 2012 Jan 20;148(1–2):150–163.
   PubMed Web of Science ®Google Scholar
• Thibodeau PH, Richardson JM 3rd, Wang W, et al. The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. J Biol Chem. 2010 Nov 12;285(46):35825–35835.
   PubMed Web of Science ®Google Scholar
• Boucher RC, Stutts MJ, Knowles MR, et al. Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. J Clin Invest. 1986 Nov;78(5):1245–1252.
   PubMed Web of Science ®Google Scholar
• Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science. 1995 Aug 11;269(5225):847–850.
   PubMed Web of Science ®Google Scholar
• Egan M, Flotte T, Afione S, et al. Defective regulation of outwardly rectifying Cl- channels by protein kinase A corrected by insertion of CFTR. Nature. 1992 Aug 13;358(6387):581–584.
   PubMed Web of Science ®Google Scholar
• Lee MG, Wigley WC, Zeng W, et al. Regulation of Cl-/HCO3- exchange by cystic fibrosis transmembrane conductance regulator expressed in NIH 3T3 and HEK 293 cells. J Biol Chem. 1999 Feb 5;274(6):3414–3421.
   PubMed Web of Science ®Google Scholar
• Hall RA, Ostedgaard LS, Premont RT, et al. A C-terminal motif found in the beta2-adrenergic receptor, P2Y1 receptor and cystic fibrosis transmembrane conductance regulator determines binding to the Na+/H+ exchanger regulatory factor family of PDZ proteins. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8496–8501.
   PubMed Web of Science ®Google Scholar
• Ismailov II, Awayda MS, Jovov B, et al. Regulation of epithelial sodium channels by the cystic fibrosis transmembrane conductance regulator. J Biol Chem. 1996 Mar 1;271(9):4725–4732.
   PubMed Web of Science ®Google Scholar
• Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998 Dec 23;95(7):1005–1015.
   PubMed Web of Science ®Google Scholar
• Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med. 2007 Jan;261(1):5–16.
   PubMed Web of Science ®Google Scholar
• O’Sullivan BP, Flume P. The clinical approach to lung disease in patients with cystic fibrosis. Semin Respir Crit Care Med. 2009 Oct;30(5):505–513.
   PubMed Web of Science ®Google Scholar
• Scortegagna M, Cataisson C, Martin RJ, et al. HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling. Blood. 2008 Apr 1;111(7):3343–3354.
   PubMed Web of Science ®Google Scholar
• Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest. 2002 Feb;109(3):317–325.
   PubMed Web of Science ®Google Scholar
• Coakley RD, Grubb BR, Paradiso AM, et al. Abnormal surface liquid pH regulation by cultured cystic fibrosis bronchial epithelium. Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):16083–16088.
   PubMed Web of Science ®Google Scholar
• Poulsen JH, Fischer H, Illek B, et al. Bicarbonate conductance and pH regulatory capability of cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5340–5344.
   PubMed Web of Science ®Google Scholar
• Welsh MJ, Smith JJ. cAMP stimulation of HCO3- secretion across airway epithelia. JOP. 2001 Jul;2(4 Suppl):291–293.
   PubMedGoogle Scholar
• Song Y, Salinas D, Nielson DW, et al. Hyperacidity of secreted fluid from submucosal glands in early cystic fibrosis. Am J Physiol Cell Physiol. 2006 Mar;290(3):C741–9.
   PubMed Web of Science ®Google Scholar
• Pezzulo AA, Tang XX, Hoegger MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature. 2012 Jul 4;487(7405):109–113.
   PubMed Web of Science ®Google Scholar
• Garcia MA, Yang N, Quinton PM. Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin Invest. 2009 Sep;119(9):2613–2622.
   PubMed Web of Science ®Google Scholar
• Gustafsson JK, Ermund A, Ambort D, et al. Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype. J Exp Med. 2012 Jul 2;209(7):1263–1272.
   PubMed Web of Science ®Google Scholar
• Hill DB, Long RF, Kissner WJ, et al. Pathological mucus and impaired mucus clearance in cystic fibrosis patients result from increased concentration, not altered pH. Eur Respir J. 2018 Dec;52(6). pii: 1801297. doi: 10.1183/13993003.01297-2018.
   Web of Science ®Google Scholar
• Schultz A, Puvvadi R, Borisov SM, et al. Airway surface liquid pH is not acidic in children with cystic fibrosis. Nat Commun. 2017 Nov 10;8(1):1409.
   PubMedGoogle Scholar
• Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011 Nov 3;365(18):1663–1672.
   PubMed Web of Science ®Google Scholar
• Donaldson SH, Laube BL, Corcoran TE, et al. Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR. JCI Insight. 2018 Dec 20;3(24). pii: 122695. doi: 10.1172/jci.insight.122695.
   PubMed Web of Science ®Google Scholar
• Hisert KB, Heltshe SL, Pope C, et al. Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections. Am J Respir Crit Care Med. 2017 Jun 15;195(12):1617–1628.
   PubMed Web of Science ®Google Scholar
• Sun T, Sun Z, Jiang Y, et al. Transcriptomic responses to ivacaftor and prediction of ivacaftor clinical responsiveness. Am J Respir Cell Mol Biol. 2019 Apr 17. doi: 10.1165/rcmb.2019-0032OC.
   Google Scholar
• Konstan MW, Krenicky JE, Finney MR, et al. Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. J Pharmacol Exp Ther. 2003 Sep;306(3):1086–1091.
   PubMed Web of Science ®Google Scholar
• Scheuren N, Bang H, Munster T, et al. Modulation of transcription factor NF-kappaB by enantiomers of the nonsteroidal drug ibuprofen. Br J Pharmacol. 1998 Feb;123(4):645–652.
   PubMed Web of Science ®Google Scholar
• Tegeder I, Niederberger E, Israr E, et al. Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen. Faseb J. 2001 Jan;15(1):2–4.
   PubMed Web of Science ®Google Scholar
• Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. Faseb J. 2001 Oct;15(12):2057–2072.
   PubMed Web of Science ®Google Scholar
• Jaradat MS, Wongsud B, Phornchirasilp S, et al. Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol. 2001 Dec 15;62(12):1587–1595.
   PubMed Web of Science ®Google Scholar
• Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995 Mar 30;332(13):848–854.
   PubMed Web of Science ®Google Scholar
• Lands LC, Milner R, Cantin AM, et al. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr. 2007 Sep;151(3):249–254.
   PubMed Web of Science ®Google Scholar
• Konstan MW, Schluchter MD, Xue W, et al. Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med. 2007 Dec 1;176(11):1084–1089.
   PubMed Web of Science ®Google Scholar
• Konstan MW, VanDevanter DR, Sawicki GS, et al. Association of high-dose ibuprofen use, lung function decline, and long-term survival in children with cystic fibrosis. Ann Am Thorac Soc. 2018 Apr;15(4):485–493.
   PubMed Web of Science ®Google Scholar
• Mogayzel PJ Jr., Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013 Apr 1;187(7):680–689.
   PubMed Web of Science ®Google Scholar
• Konstan MW. Ibuprofen therapy for cystic fibrosis lung disease: revisited. Curr Opin Pulm Med. 2008 Nov;14(6):567–573.
   PubMed Web of Science ®Google Scholar
• Auerbach HS, Williams M, Kirkpatrick JA, et al. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet. 1985 Sep 28;2(8457):686–688.
   PubMed Web of Science ®Google Scholar
• Eigen H, Rosenstein BJ, FitzSimmons S, et al. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic fibrosis foundation prednisone trial group. J Pediatr. 1995 Apr;126(4):515–523.
   PubMed Web of Science ®Google Scholar
• Lai HC, FitzSimmons SC, Allen DB, et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med. 2000 Mar 23;342(12):851–859.
   PubMed Web of Science ®Google Scholar
• Donati M, Haver K, Gerson W, et al. Long-term alternate day prednisone therapy in cystic fibrosis. Pediatr Pulmonol. 1990;5:A322.
   Google Scholar
• Ren CL, Pasta DJ, Rasouliyan L, et al. Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr. 2008 Dec;153(6):746–751.
   PubMed Web of Science ®Google Scholar
• Balfour-Lynn IM, Klein NJ, Dinwiddie R. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child. 1997 Aug;77(2):124–130.
   PubMed Web of Science ®Google Scholar
• Balfour-Lynn IM, Lees B, Hall P, et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med. 2006 Jun 15;173(12):1356–1362.
   PubMed Web of Science ®Google Scholar
• Dauletbaev N, Viel K, Behr J, et al. Effects of short-term inhaled fluticasone on oxidative burst of sputum cells in cystic fibrosis patients. Eur Respir J. 1999 Nov;14(5):1150–1155.
   PubMed Web of Science ®Google Scholar
• Nikolaizik WH, Schoni MH. Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. J Pediatr. 1996 Feb;128(2):271–274.
   PubMed Web of Science ®Google Scholar
• van Haren EH, Lammers JW, Festen J, et al. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir Med. 1995 Mar;89(3):209–214.
   PubMed Web of Science ®Google Scholar
• Wojtczak HA, Kerby GS, Wagener JS, et al. Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: a pilot study. Pediatr Pulmonol. 2001 Oct;32(4):293–302.
   PubMed Web of Science ®Google Scholar
• Hedstrom L. Serine protease mechanism and specificity. Chem Rev. 2002 Dec;102(12):4501–4524.
   PubMed Web of Science ®Google Scholar
• Fouret P, du Bois RM, Bernaudin JF, et al. Expression of the neutrophil elastase gene during human bone marrow cell differentiation. J Exp Med. 1989 Mar 1;169(3):833–845.
   PubMed Web of Science ®Google Scholar
• Zimmer M, Medcalf RL, Fink TM, et al. Three human elastase-like genes coordinately expressed in the myelomonocyte lineage are organized as a single genetic locus on 19pter. Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8215–8219.
   PubMed Web of Science ®Google Scholar
• Sommerhoff CP, Krell RD, Williams JL, et al. Inhibition of human neutrophil elastase by ICI 200,355. Eur J Pharmacol. 1991 Feb 7;193(2):153–158.
   PubMed Web of Science ®Google Scholar
• Stockley RA. Role of inflammation in respiratory tract infections. Am J Med. 1995 Dec 29;99(6B):8S–13S.
   PubMedGoogle Scholar
• Fick RB Jr., Naegel GP, Squier SU, et al. Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. J Clin Invest. 1984 Jul;74(1):236–248.
   PubMed Web of Science ®Google Scholar
• Berger M, Sorensen RU, Tosi MF, et al. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest. 1989 Oct;84(4):1302–1313.
   PubMed Web of Science ®Google Scholar
• Tosi MF, Zakem H, Berger M. Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest. 1990 Jul;86(1):300–308.
   PubMed Web of Science ®Google Scholar
• Le Gars M, Descamps D, Roussel D, et al. Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo. Am J Respir Crit Care Med. 2013 Jan 15;187(2):170–179.
   PubMed Web of Science ®Google Scholar
• Walsh DE, Greene CM, Carroll TP, et al. Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6 in human bronchial epithelium. J Biol Chem. 2001 Sep 21;276(38):35494–35499.
   PubMed Web of Science ®Google Scholar
• Hubbard RC, Fells G, Gadek J, et al. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest. 1991 Sep;88(3):891–897.
   PubMed Web of Science ®Google Scholar
• Weldon S, McNally P, McElvaney NG, et al. Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. J Immunol. 2009 Dec 15;183(12):8148–8156.
   PubMed Web of Science ®Google Scholar
• McElvaney NG. Alpha-1 antitrypsin therapy in cystic fibrosis and the lung disease associated with alpha-1 antitrypsin deficiency. Ann Am Thorac Soc. 2016 Apr;13(Suppl 2):S191–6.
   PubMedGoogle Scholar
• Carrell RW, Jeppsson JO, Laurell CB, et al. Structure and variation of human alpha 1-antitrypsin. Nature. 1982 Jul 22;298(5872):329–334.
   PubMed Web of Science ®Google Scholar
• Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci U S A. 1986 Sep;83(18):6692–6696.
   PubMed Web of Science ®Google Scholar
• Sagel SD, Sontag MK, Wagener JS, et al. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. J Pediatr. 2002 Dec;141(6):811–817.
   PubMed Web of Science ®Google Scholar
• Owen CA, Campbell EJ. The cell biology of leukocyte-mediated proteolysis. J Leukoc Biol. 1999 Feb;65(2):137–150.
   PubMed Web of Science ®Google Scholar
• Amitani R, Wilson R, Rutman A, et al. Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium. Am J Respir Cell Mol Biol. 1991 Jan;4(1):26–32.
   PubMed Web of Science ®Google Scholar
• Ying QL, Simon SR. Elastolysis by proteinase 3 and its inhibition by alpha(1)-proteinase inhibitor: a mechanism for the incomplete inhibition of ongoing elastolysis. Am J Respir Cell Mol Biol. 2002 Mar;26(3):356–361.
   PubMed Web of Science ®Google Scholar
• Falk RJ, Terrell RS, Charles LA, et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990 Jun;87(11):4115–4119.
   PubMed Web of Science ®Google Scholar
• Franssen CF, Huitema MG, Muller Kobold AC, et al. In vitro neutrophil activation by antibodies to proteinase 3 and myeloperoxidase from patients with crescentic glomerulonephritis. J Am Soc Nephrol. 1999 Jul;10(7):1506–1515.
   PubMed Web of Science ®Google Scholar
• Bank U, Ansorge S. More than destructive: neutrophil-derived serine proteases in cytokine bioactivity control. J Leukoc Biol. 2001 Feb;69(2):197–206.
   PubMed Web of Science ®Google Scholar
• Odeberg H, Olsson I. Antibacterial activity of cationic proteins from human granulocytes. J Clin Invest. 1975 Nov;56(5):1118–1124.
   PubMed Web of Science ®Google Scholar
• Duranton J, Bieth JG. Inhibition of proteinase 3 by [alpha]1-antitrypsin in vitro predicts very fast inhibition in vivo. Am J Respir Cell Mol Biol. 2003 Jul;29(1):57–61.
   PubMed Web of Science ®Google Scholar
• Vercaigne-Marko D, Davril M, Laine A, et al. Interaction of human alpha 1-proteinase inhibitor with human leukocyte cathepsin G. Biol Chem Hoppe-Seyler. 1985 Jul;366(7):655–661.
   PubMed Web of Science ®Google Scholar
• Rawlings ND, Tolle DP, Barrett AJ. Evolutionary families of peptidase inhibitors. Biochem J. 2004 Mar 15;378(Pt 3):705–716.
   PubMedGoogle Scholar
• Gettins PG. Serpin structure, mechanism, and function. Chem Rev. 2002 Dec;102(12):4751–4804.
   PubMed Web of Science ®Google Scholar
• Lawrence DA, Olson ST, Palaniappan S, et al. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition. J Biol Chem. 1994 Nov 4;269(44):27657–27662.
   PubMed Web of Science ®Google Scholar
• Lai EC, Kao FT, Law ML, et al. Assignment of the alpha 1-antitrypsin gene and a sequence-related gene to human chromosome 14 by molecular hybridization. Am J Hum Genet. 1983 May;35(3):385–392.
   PubMed Web of Science ®Google Scholar
• Paakko P, Kirby M, du Bois RM, et al. Activated neutrophils secrete stored alpha 1-antitrypsin. Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1829–1833.
   PubMed Web of Science ®Google Scholar
• Perlmutter DH, Cole FS, Kilbridge P, et al. Expression of the alpha 1-proteinase inhibitor gene in human monocytes and macrophages. Proc Natl Acad Sci U S A. 1985 Feb;82(3):795–799.
   PubMed Web of Science ®Google Scholar
• Venembre P, Boutten A, Seta N, et al. Secretion of alpha 1-antitrypsin by alveolar epithelial cells. FEBS Lett. 1994 Jun 13;346(2–3):171–174.
   PubMed Web of Science ®Google Scholar
• Jones EA, Vergalla J, Steer CJ, et al. Metabolism of intact and desialylated alpha 1-antitrypsin. Clin Sci Mol Med. 1978 Aug;55(2):139–148.
   PubMedGoogle Scholar
• Beatty K, Bieth J, Travis J. Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin. J Biol Chem. 1980 May 10;255(9):3931–3934.
   PubMed Web of Science ®Google Scholar
• McElvaney NG, Hubbard RC, Birrer P, et al. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet. 1991 Feb 16;337(8738):392–394.
   PubMed Web of Science ®Google Scholar
• Berger MKMHJ. Aerosolized prolastin (α1-protease inhibitor) in CF. Pediatr Pulmonol. 1995.
   Google Scholar
• McElvaney NG, Nakamura H, Birrer P, et al. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest. 1992 Oct;90(4):1296–1301.
   PubMed Web of Science ®Google Scholar
• Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463–516.
   PubMed Web of Science ®Google Scholar
• Butler GS, Will H, Atkinson SJ, et al. Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases. Eur J Biochem. 1997 Mar 1;244(2):653–657.
   PubMedGoogle Scholar
• Sato H, Kinoshita T, Takino T, et al. Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett. 1996 Sep 9;393(1):101–104.
   PubMed Web of Science ®Google Scholar
• Zucker S, Drews M, Conner C, et al. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem. 1998 Jan 9;273(2):1216–1222.
   PubMed Web of Science ®Google Scholar
• Will H, Atkinson SJ, Butler GS, et al. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J Biol Chem. 1996 Jul 19;271(29):17119–17123.
   PubMed Web of Science ®Google Scholar
• Delacourt C, Le Bourgeois M, D’Ortho MP, et al. Imbalance between 95 kDa type IV collagenase and tissue inhibitor of metalloproteinases in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med. 1995 Aug;152(2):765–774.
   PubMed Web of Science ®Google Scholar
• Dunsmore SE, Saarialho-Kere UK, Roby JD, et al. Matrilysin expression and function in airway epithelium. J Clin Invest. 1998 Oct 1;102(7):1321–1331.
   PubMed Web of Science ®Google Scholar
• Gaggar A, Li Y, Weathington N, et al. Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. Am J Physiol Lung Cell Mol Physiol. 2007 Jul;293(1):L96–L104.
   PubMed Web of Science ®Google Scholar
• Ratjen F, Hartog CM, Paul K, et al. Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha. Thorax. 2002 Nov;57(11):930–934.
   PubMed Web of Science ®Google Scholar
• Krzeski P, Buckland-Wright C, Balint G, et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther. 2007;9(5):R109.
   PubMed Web of Science ®Google Scholar
• Xu X, Abdalla T, Bratcher PE, et al. Doxycycline improves clinical outcomes during cystic fibrosis exacerbations. Eur Respir J. 2017 Apr;49(4):1601102.
   PubMed Web of Science ®Google Scholar
• Taggart CC, Greene CM, Smith SG, et al. Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. J Immunol. 2003 Jul 15;171(2):931–937.
   PubMed Web of Science ®Google Scholar
• Rogan MP, Taggart CC, Greene CM, et al. Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J Infect Dis. 2004 Oct 1;190(7):1245–1253.
   PubMed Web of Science ®Google Scholar
• Taggart CC, Lowe GJ, Greene CM, et al. Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem. 2001 Sep 7;276(36):33345–33352.
   PubMed Web of Science ®Google Scholar
• Geraghty P, Greene CM, O’Mahony M, et al. Secretory leucocyte protease inhibitor inhibits interferon-gamma-induced cathepsin S expression. J Biol Chem. 2007 Nov 16;282(46):33389–33395.
   PubMed Web of Science ®Google Scholar
• Dean TP, Dai Y, Shute JK, et al. Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis. Pediatr Res. 1993 Aug;34(2):159–161.
   PubMed Web of Science ®Google Scholar
• Tabary O, Escotte S, Couetil JP, et al. High susceptibility for cystic fibrosis human airway gland cells to produce IL-8 through the I kappa B kinase alpha pathway in response to extracellular NaCl content. J Immunol. 2000 Mar 15;164(6):3377–3384.
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan A, Stecenko AA, King G, et al. Exaggerated activation of nuclear factor-kappaB and altered IkappaB-beta processing in cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol. 2000 Sep;23(3):396–403.
   PubMed Web of Science ®Google Scholar
• Tabary O, Zahm JM, Hinnrasky J, et al. Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro. Am J Pathol. 1998 Sep;153(3):921–930.
   PubMed Web of Science ®Google Scholar
• Barton RW, Rothlein R, Ksiazek J, et al. The effect of anti-intercellular adhesion molecule-1 on phorbol-ester-induced rabbit lung inflammation. J Immunol. 1989 Aug 15;143(4):1278–1282.
   PubMed Web of Science ®Google Scholar
• Reeves EP, Williamson M, O’Neill SJ, et al. Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med. 2011 Jun 1;183(11):1517–1523.
   PubMed Web of Science ®Google Scholar
• McElvaney OJ, O’Reilly N, White M, et al. The effect of the decoy molecule PA401 on CXCL8 levels in bronchoalveolar lavage fluid of patients with cystic fibrosis. Mol Immunol. 2015 Feb;63(2):550–558.
   PubMed Web of Science ®Google Scholar
• Moss RB, Mistry SJ, Konstan MW, et al. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. J Cyst Fibros. 2013 May;12(3):241–248.
   PubMed Web of Science ®Google Scholar
• Rennard SI, Dale DC, Donohue JF, et al. CXCR2 antagonist MK-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015 May 1;191(9):1001–1011.
   PubMed Web of Science ®Google Scholar
• Konstan MW, Walenga RW, Hilliard KA, et al. Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis. 1993 Oct;148(4 Pt 1):896–901.
   PubMedGoogle Scholar
• Konstan MW, Doring G, Heltshe SL, et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros. 2014 Mar;13(2):148–155.
   PubMed Web of Science ®Google Scholar
• Doring G, Bragonzi A, Paroni M, et al. BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. . J Cyst Fibros. 2014 Mar;13(2):156–163.
   PubMed Web of Science ®Google Scholar
• Elborn JS, Bhatt L, Grosswald R, et al. Phase I studies of acebilustat: pharmacokinetics, pharmacodynamics, food effect, and CYP3A induction. Clin Transl Sci. 2017 Jan;10(1):20–27.
   PubMed Web of Science ®Google Scholar
• Elborn JS, Horsley A, MacGregor G, et al. Phase I studies of acebilustat: biomarker response and safety in patients with cystic fibrosis. Clin Transl Sci. 2017 Jan;10(1):28–34.
   PubMed Web of Science ®Google Scholar
• Brodlie M, McKean MC, Johnson GE, et al. Raised interleukin-17 is immunolocalised to neutrophils in cystic fibrosis lung disease. Eur Respir J. 2011 Jun;37(6):1378–1385.
   PubMed Web of Science ®Google Scholar
• McAllister F, Henry A, Kreindler JL, et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol. 2005 Jul 1;175(1):404–412.
   PubMed Web of Science ®Google Scholar
• Patel DD, Lee DM, Kolbinger F, et al. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013 Apr;72(Suppl 2):ii116–23.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012 Mar 29;366(13):1190–1199.
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012 Dec;61(12):1693–1700.
   PubMed Web of Science ®Google Scholar
• Hull J, Vervaart P, Grimwood K, et al. Pulmonary oxidative stress response in young children with cystic fibrosis. Thorax. 1997 Jun;52(6):557–560.
   PubMed Web of Science ®Google Scholar
• Roum JH, Borok Z, McElvaney NG, et al. Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis. J Appl Physiol (1985). 1999 Jul;87(1):438–443.
   PubMed Web of Science ®Google Scholar
• Roum JH, Buhl R, McElvaney NG, et al. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol (1985). 1993 Dec;75(6):2419–2424.
   PubMed Web of Science ®Google Scholar
• Bishop C, Hudson VM, Hilton SC, et al. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest. 2005 Jan;127(1):308–317.
   PubMed Web of Science ®Google Scholar
• Hartl D, Starosta V, Maier K, et al. Inhaled glutathione decreases PGE2 and increases lymphocytes in cystic fibrosis lungs. Free Radic Biol Med. 2005 Aug 15;39(4):463–472.
   PubMed Web of Science ®Google Scholar
• Griese M, Kappler M, Eismann C, et al. Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med. 2013 Jul 1;188(1):83–89.
   PubMed Web of Science ®Google Scholar
• Calabrese C, Tosco A, Abete P, et al. Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis. J Cyst Fibros. 2015 Mar;14(2):203–210.
   PubMed Web of Science ®Google Scholar
• Tirouvanziam R, Conrad CK, Bottiglieri T, et al. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4628–4633.
   PubMed Web of Science ®Google Scholar
• Conrad C, Lymp J, Thompson V, et al. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. J Cyst Fibros. 2015 Mar;14(2):219–227.
   PubMed Web of Science ®Google Scholar
• Sagel SD, Khan U, Jain R, et al. Effects of an antioxidant-enriched multivitamin in cystic fibrosis. A randomized, controlled, multicenter clinical trial. Am J Respir Crit Care Med. 2018 Sep 1;198(5):639–647.
   PubMed Web of Science ®Google Scholar
• McNally P, Coughlan C, Bergsson G, et al. Vitamin D receptor agonists inhibit pro-inflammatory cytokine production from the respiratory epithelium in cystic fibrosis. J Cyst Fibros. 2011 Dec;10(6):428–434.
   PubMed Web of Science ®Google Scholar
• Kreindler JL, Steele C, Nguyen N, et al. Vitamin D3 attenuates Th2 responses to Aspergillus fumigatus mounted by CD4+ T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. J Clin Invest. 2010 Sep;120(9):3242–3254.
   PubMed Web of Science ®Google Scholar
• Coughlan CA, Chotirmall SH, Renwick J, et al. Itraconazole up-regulates the vitamin D receptor and reduces T-helper 2 responses in Aspergillus fumigatus colonised individuals with cystic fibrosis. In; B35. Pathogenesis and clinical issues in cystic fibrosis. American Thoracic Society; 2012. p. A2807–A2807.
   Google Scholar
• Cigana C, Nicolis E, Pasetto M, et al. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun. 2006 Dec 1;350(4):977–982.
   PubMed Web of Science ®Google Scholar
• Tsai WC, Rodriguez ML, Young KS, et al. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med. 2004 Dec 15;170(12):1331–1339.
   PubMed Web of Science ®Google Scholar
• Clement A, Tamalet A, Leroux E, et al. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax. 2006 Oct;61(10):895–902.
   PubMed Web of Science ®Google Scholar
• Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2010 May 5;303(17):1707–1715.
   PubMed Web of Science ®Google Scholar
• Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003 Oct 1;290(13):1749–1756.
   PubMed Web of Science ®Google Scholar
• Tramper-Stranders GA, Wolfs TF, Fleer A, et al. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J. 2007 Jan;26(1):8–12.
   PubMed Web of Science ®Google Scholar
• Mayer-Hamblett N, Retsch-Bogart G, Kloster M, et al. Azithromycin for early Pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. Am J Respir Crit Care Med. 2018 Nov 1;198(9):1177–1187.
   PubMed Web of Science ®Google Scholar
• Nichols DP, Happoldt CL, Bratcher PE, et al. Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis. J Cyst Fibros. 2017 May;16(3):358–366.
   PubMed Web of Science ®Google Scholar
• Caceres SM, Malcolm KC, Taylor-Cousar JL, et al. Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products. Antimicrob Agents Chemother. 2014 Nov;58(11):6851–6860.
   PubMed Web of Science ®Google Scholar
• Nick JA, Moskowitz SM, Chmiel JF, et al. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc. 2014 Mar;11(3):342–350.
   PubMedGoogle Scholar
• Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med. 1993 Jun 17;328(24):1740–1746.
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic fibrosis inhaled tobramycin study group. N Engl J Med. 1999 Jan 7;340(1):23–30.
   PubMed Web of Science ®Google Scholar
• Noah TL, Ivins SS, Abode KA, et al. Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas. Pediatr Pulmonol. 2010 Mar;45(3):281–290.
   PubMed Web of Science ®Google Scholar
• Milla CE, Chmiel JF, Accurso FJ, et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr Pulmonol. 2014;49(7):650–658.
   PubMed Web of Science ®Google Scholar
• Jain R, Beckett VV, Konstan MW, et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. J Cyst Fibros. 2018 Jul;17(4):484–491.
   PubMed Web of Science ®Google Scholar
• White MM, Geraghty P, Hayes E, et al. Neutrophil membrane cholesterol content is a key factor in cystic fibrosis lung disease. EBioMedicine. 2017;23:173–184.
   PubMed Web of Science ®Google Scholar
• Teichgraber V, Ulrich M, Endlich N, et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med. 2008 Apr;14(4):382–391.
   PubMed Web of Science ®Google Scholar
• Becker KA, Henry B, Ziobro R, et al. Lipids in cystic fibrosis. Expert Rev Respir Med. 2011 Aug;5(4):527–535.
   PubMed Web of Science ®Google Scholar
• Grassme H, Jendrossek V, Riehle A, et al. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med. 2003 Mar;9(3):322–330.
   PubMed Web of Science ®Google Scholar
• Becker KA, Riethmuller J, Luth A, et al. Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. Am J Respir Cell Mol Biol. 2010 Jun;42(6):716–724.
   PubMed Web of Science ®Google Scholar
• Becker KA, Tummler B, Gulbins E, et al. Accumulation of ceramide in the trachea and intestine of cystic fibrosis mice causes inflammation and cell death. Biochem Biophys Res Commun. 2010 Dec 17;403(3–4):368–374.
   PubMed Web of Science ®Google Scholar
• Guilbault C, De Sanctis JB, Wojewodka G, et al. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. Am J Respir Cell Mol Biol. 2008 Jan;38(1):47–56.
   PubMed Web of Science ®Google Scholar
• Guilbault C, Wojewodka G, Saeed Z, et al. Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide. Am J Respir Cell Mol Biol. 2009 Jul;41(1):100–106.
   PubMed Web of Science ®Google Scholar
• Worgall TS. Lipid metabolism in cystic fibrosis. Curr Opin Clin Nutr Metab Care. 2009 Mar;12(2):105–109.
   PubMed Web of Science ®Google Scholar
• Nahrlich L, Mainz JG, Adams C, et al. Therapy of CF-patients with amitriptyline and placebo–a randomised, double-blind, placebo-controlled phase IIb multicenter, cohort-study. Cell Physiol Biochem. 2013;31(4–5):505–512.
   PubMedGoogle Scholar
• Freedman SD, Blanco PG, Zaman MM, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med. 2004 Feb 5;350(6):560–569.
   PubMed Web of Science ®Google Scholar
• Aldamiz-Echevarria L, Prieto JA, Andrade F, et al. Persistence of essential fatty acid deficiency in cystic fibrosis despite nutritional therapy. Pediatr Res. 2009 Nov;66(5):585–589.
   PubMed Web of Science ®Google Scholar
• Van Biervliet S, Devos M, Delhaye T, et al. Oral DHA supplementation in deltaF508 homozygous cystic fibrosis patients. Prostaglandins Leukot Essent Fatty Acids. 2008 Feb;78(2):109–115.
   PubMed Web of Science ®Google Scholar
• Maderna P, Godson C. Taking insult from injury: lipoxins and lipoxin receptor agonists and phagocytosis of apoptotic cells. Prostaglandins Leukot Essent Fatty Acids. 2005 Sep–Oct;73(3–4):179–187.
   PubMed Web of Science ®Google Scholar
• McMahon B, Godson C. Lipoxins: endogenous regulators of inflammation. Am J Physiol Renal Physiol. 2004 Feb;286(2):F189–201.
   PubMed Web of Science ®Google Scholar
• Parkinson JF. Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation. Inflamm Allergy Drug Targets. 2006 Apr;5(2):91–106.
   PubMedGoogle Scholar
• Karp CL, Flick LM, Park KW, et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol. 2004 Apr;5(4):388–392.
   PubMed Web of Science ®Google Scholar
• Ringholz FC, Buchanan PJ, Clarke DT, et al. Reduced 15-lipoxygenase 2 and lipoxin A4/leukotriene B4 ratio in children with cystic fibrosis. Eur Respir J. 2014 Aug;44(2):394–404.
   PubMed Web of Science ®Google Scholar
• Corminboeuf O, Leroy X. FPR2/ALXR agonists and the resolution of inflammation. J Med Chem. 2015 Jan 22;58(2):537–559.
   PubMed Web of Science ®Google Scholar
• Uddin M, Levy BD. Resolvins: natural agonists for resolution of pulmonary inflammation. Prog Lipid Res. 2011 Jan;50(1):75–88.
   PubMed Web of Science ®Google Scholar
• Serhan CN, Fredman G, Yang R, et al. Novel proresolving aspirin-triggered DHA pathway. Chem Biol. 2011 Aug 26;18(8):976–987.
   PubMedGoogle Scholar
• Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995 Aug 15;232(1):54–61.
   PubMedGoogle Scholar
• Basu S, Dittel BN. Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res. 2011 Oct;51(1):26–38.
   PubMed Web of Science ®Google Scholar
• Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005 May;5(5):400–411.
   PubMed Web of Science ®Google Scholar
• Zurier RB, Sun YP, George KL, et al. Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4. Faseb J. 2009 May;23(5):1503–1509.
   PubMed Web of Science ®Google Scholar
• Chmiel JF, Elborn JS, Scott Constantine M, et al. A phase 2 study of the safety, pharmacokinetics and efficacy of anabasum (JBT-101) in Cystic Fibrosis (CF). J Cyst Fibros. 2017;16:S01. 05.
   Google Scholar